Skip to main content
. 2015 Nov 23;112(49):E6752–E6761. doi: 10.1073/pnas.1520957112

Fig. 4.

Fig. 4.

Transport intermediates and regulators of the Golgi-to-ER retrograde pathway mediating cycling of Golgi enzymes. (A) Time-lapse confocal images showing a transport carrier breaking off from a tubule (red arrowhead) originating from the Golgi apparatus in rapamycin-treated cells coexpressing SiT-FRB-EGFP and Ii-FKBP12-mRFP. (Scale bar: 2 μm.) (B) HeLa cells coexpressing SiT-FRB-EGFP and Ii-FKBP12-mRFP were imaged after treatment with cycloheximide + rapamycin ± BEL for 4 h. (Scale bar: 10 μm.) (C) Percentage of cells from B with minimal, partial, and major amounts of SiT fluorescence in the ER following 4 h of incubation with cycloheximide + rapamycin ± BEL. (D) Confocal images of cells coexpressing Man II-FRB-Venus, Ii-FKBP12-Cer, and either myc-tagged WT rab6a (Top) or myc-tagged, dominant-negative, GDP-bound rab6a-T27N (Bottom) following treatment with cycloheximide ± rapamycin for 4 h. (Scale bar: 10 μm.) (E) Percentage of cells coexpressing Man II-FRB-Venus, Ii-FKBP12-Cer, and the indicated rab6a construct, with minimal, partial, and major amounts of Man II fluorescence in the ER following 4 h treatment with cycloheximide + rapamycin. At least 60 cells were analyzed for each condition.